Patents Examined by Misook Yu
-
Patent number: 12325734Abstract: Engineered TCR molecules specific to retroviral peptide/HLA complexes guide direct killing and/or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (V?) domain, a TCR variable beta domain (V?) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.Type: GrantFiled: January 15, 2020Date of Patent: June 10, 2025Assignees: Altor Bioscience LLC, The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Peter Rhode, Mark Connors, Stephen Migueles
-
Patent number: 12325748Abstract: Provided are an anti-PDL1 antibody and an antigen-binding fragment thereof, and further provided are a bifunctional fusion protein against PDL1 and TGF? and a preparation method thereof and the use thereof. The antibody or antigen-binding fragment or the bifunctional fusion protein has one or more of the following advantages: an enhanced TGF?1 binding activity, an enhanced affinity to PDL1, an enhanced ability to block the binding of PDL1 and PD1, an enhanced functional activity for blocking TGF? 1, an enhanced ability to promote the secretion of IFN-? by T cells, a better immunomodulatory effect and a better tumor inhibitory effect.Type: GrantFiled: June 8, 2020Date of Patent: June 10, 2025Assignee: Shandong Boan Biotechnology Co., Ltd.Inventors: Deyong Song, Hongguang Xu, Zhen Han
-
Patent number: 12325749Abstract: Provided is an isolated antibody or antigen-binding fragment thereof that binds specifically to human CD-L1 protein, a nucleic acid molecule encoding the same, therapeutic compositions thereof, and their use to treat a PD-L1 related disease, such as a tumor which is PD-L1 positive.Type: GrantFiled: July 19, 2019Date of Patent: June 10, 2025Assignee: Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd.Inventors: Tong Zhou, Fengqi Cao, Zhe Li, Xiuli Jin
-
Patent number: 11911469Abstract: The present disclosure provides methods and compositions for the treatment of cancer using an ACAT1 inhibitor in combination with an immune checkpoint inhibitor. The immune checkpoint inhibitor may inhibit the programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation protein 3 (LAG-3), or combinations thereof. The ACAT1 inhibitor may be avasimibe, pactimibe, or purpactins, without limitation.Type: GrantFiled: January 11, 2017Date of Patent: February 27, 2024Assignee: Center for Excellence in Molecular Cell Science, Chinese Academy of ScienesInventors: Chenqi Xu, Boliang Li, Wei Yang, Yibing Bai, Ying Xiong
-
Patent number: 11857624Abstract: A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule which encodes the OPCML polypeptide or fragment or variant thereof.Type: GrantFiled: May 22, 2020Date of Patent: January 2, 2024Assignee: PAPYRUS THERAPEUTICS, INC.Inventor: Hani Gabra
-
Patent number: 11845793Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.Type: GrantFiled: October 31, 2016Date of Patent: December 19, 2023Assignee: NBE-THERAPEUTICS AGInventors: Lorenz Waldmeier, Ulf Grawunder, Roger Beerli
-
Patent number: 11840572Abstract: The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.Type: GrantFiled: July 16, 2021Date of Patent: December 12, 2023Assignee: Pfizer Inc.Inventors: James Reasoner Apgar, Andrea Therese Hooper, Malgorzata Agnieszka Nocula-Lugowska, Lei Wu
-
Patent number: 11827697Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.Type: GrantFiled: February 2, 2019Date of Patent: November 28, 2023Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.Inventors: Yaping Yang, Nanmeng Song, Wenchu Xiao, Zhenlei Li, Lina Zhang, Mingyue Gu, Chunguang Zhan, Jiawang Liu, Maengsup Kim
-
Patent number: 11795210Abstract: Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.Type: GrantFiled: July 14, 2020Date of Patent: October 24, 2023Assignee: Gilead Sciences, Inc.Inventors: Xinan Liu, Azure T. Makadzange, Stephen R. Martin, Hesham Shehata, Evguenia Svarovskaia
-
Patent number: 11793843Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.Type: GrantFiled: January 9, 2020Date of Patent: October 24, 2023Assignee: Janssen Biotech, Inc.Inventors: Kurtis E. Bachman, Vipul Bhargava, Darryl L. Davis, Vinod Krishna, Guido Leoni, David Pocalyko, Pegah Safabakhsh, Manuel Sepulveda, Derick Siegel, Marco Gottardis
-
Patent number: 11597772Abstract: The present invention relates to obinutuzumab (or its functional equivalents) for use in the treatment of a particular biomarker-defined DLBCL patient and a novel DLBCL patient subgroup, respectively. The present invention further relates to a method for treating DLBCL with obinutuzumab (or its functional equivalents) in a patient in need thereof, wherein said patient is a particular biomarker-defined DLBCL patient or belongs to a novel biomarker-defined DLBCL patient subgroup. The present invention further relates to the use of obinutuzumab (or its functional equivalents) for the preparation of a pharmaceutical composition for the treatment of DLBCL in the particular biomarker-defined DLBCL patient/novel DLBCL patient subgroup. The present invention further relates to a method for identifying a particular DLBCL patient/novel DLBCL patient subgroup and a method for diagnosing a novel form of DLBCL and a particular DLBCL patient/novel DLBCL patient subgroup, respectively.Type: GrantFiled: February 6, 2020Date of Patent: March 7, 2023Inventor: Mikkel Zahle Oestergaard
-
Patent number: 11485782Abstract: Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.Type: GrantFiled: March 14, 2019Date of Patent: November 1, 2022Assignee: Beijing Xuanyi Pharmasciences Co., Ltd.Inventors: Yuntao Song, Yi Ding, Chen Dong, Zhiwei Li, John Lippincott, Ping Hui Szu
-
Patent number: 11479611Abstract: The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.Type: GrantFiled: June 2, 2020Date of Patent: October 25, 2022Assignee: China Medical University HospitalInventors: Der-Yang Cho, Shao-Chih Chiu, Chia-Ing Jan, Chih-Ming Pan, Shi-Wei Huang
-
Patent number: 11473151Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g.Type: GrantFiled: May 5, 2020Date of Patent: October 18, 2022Assignee: Genentech, Inc.Inventors: Yinghui Guan, Yasin Senbabaoglu, Shannon Turley, Yulei Wang
-
Patent number: 11446368Abstract: A vaccine containing an epitope of a heat shock protein 90 and uses thereof are disclosed. The epitope(s) of heat shock protein 90 has the amino acid sequence of SEQ ID NO: 1 and/or 2. A multi-epitope vaccine containing the epitope(s) and a method for treating or preventing cancer using the same are disclosed.Type: GrantFiled: August 19, 2020Date of Patent: September 20, 2022Assignee: ASTON SCI. CO., LTD.Inventors: Kyong Hwa Park, Jinho Kang
-
Patent number: 11442065Abstract: The invention provides that OSTERIX (a.k.a. SP7) is a marker for gastrointestinal stem cells and that OSTERIX is expressed widely and at elevated levels in human gastrointestinal tumors.Type: GrantFiled: March 30, 2020Date of Patent: September 13, 2022Assignee: Rhode Island HospitalInventors: Wentian Yang, Lijun Wang, Douglas C. Moore
-
Patent number: 11427636Abstract: Described herein are novel anti-PD1 antibody reagents (e.g., antibodies, antigen-binding fragments thereof, and/or chimeric antigen receptors). Also described herein antibody-drug conjugates or kits comprising the disclosed antibody reagents, as well as methods of treating cancer by administering the disclosed antibody reagents.Type: GrantFiled: May 1, 2018Date of Patent: August 30, 2022Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Frederick W. Alt, Ming Tian, Hwei-Ling Cheng
-
Patent number: 11366117Abstract: The present invention discloses an application of the exosome T?RII protein as a marker in preparing a breast cancer diagnostic kit, and belongs to the technology field of breast cancer detection kits. The present invention finds that the content of T?RII positive exosomes in the serum of breast cancer patients is significantly higher than these of healthy people, and after the surgery, the content of T?RII exosomes in the serum of breast cancer patients reduces significantly, which suggests the value of the T?RII positive exosomes during the diagnosis and prognosis of breast cancer. The present invention provides a breast cancer diagnosis kit based on detecting exosome T?RII protein in peripheral blood, which is simple in operation, and only needs to extract a small amount of peripheral blood of the test population, thereby detecting whether the test population has breast cancer and evaluating the tumor of the patient. The degree of malignancy and the state of metastasis.Type: GrantFiled: June 5, 2019Date of Patent: June 21, 2022Assignee: ZHEJIANG UNIVERSITYInventors: Long Zhang, Feng Xie
-
Patent number: 11332773Abstract: The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.Type: GrantFiled: July 31, 2018Date of Patent: May 17, 2022Assignee: KEIO UNIVERSITYInventors: Shigeto Shimmura, Shin Hatou, Emi Inagaki, Kazuo Tsubota
-
Patent number: 11090322Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.Type: GrantFiled: November 1, 2018Date of Patent: August 17, 2021Assignee: Genentech, Inc.Inventors: John A. Flygare, Thomas H. Pillow